Pavankumar Tandra, MD
Medical Oncology · Chicago, ILNPI 1477879567
Payments from drug & device makers
Across 250 payments — averaging $1419.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$168K
- Jazz Pharmaceuticals Inc.$159K
- Daiichi Sankyo Inc.$25K
- Pfizer$1K
- Gilead$377
- Novartis$248
- plus $1K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $167,744 |
| Jazz Pharmaceuticals Inc. | 112 | $158,732 |
| Daiichi Sankyo Inc. | 20 | $25,009 |
| Pfizer | 9 | $1,418 |
| Gilead(2 entities) | 20 | $377 |
| Novartis | 16 | $248 |
| E.r. Squibb & Sons, L.L.C. | 13 | $240 |
| Merck | 7 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $140 |
| Array Biopharma Inc | 6 | $129 |
| Idorsia Pharmaceuticals US Inc | 1 | $126 |
| Taiho Oncology, Inc. | 6 | $99 |
| GSK | 4 | $75 |
| Seagen Inc. | 3 | $57 |
| Bristol Myers Squibb | 2 | $47 |
| Incyte Corporation | 2 | $42 |
| Genmab U.S., Inc. | 2 | $36 |
| Exelixis Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $28 |
| AbbVie | 1 | $28 |
| Sumitomo Pharma America, Inc. | 2 | $27 |
| Beigene USA, Inc. | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Iovance Biotherapeutics, Inc. | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Beone Medicines USA, Inc. | 1 | $14 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
| Veracyte, Inc. | 1 | $5 |
How this compares
$354,995 in reported general payments places this provider in the 75th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Chicago
- Andrzej JakubowiakChicago$42M
- Alexander PearsonChicago$9.3M
- Jyoti PatelChicago$7.5M
- Devalingam MahalingamChicago$7.1M
- Ardaman ShergillChicago$4.9M
- Sunandana ChandraChicago$4.6M
- William GradisharChicago$3.3M
- Manali BhaveChicago$3.3M
- Eugene AhnChicago$2.8M
- Nisha MohindraChicago$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.